To compare perioperative and functional outcomes of patients with cT1a or cT1b renal masses undergoing robotic partial nephrectomy (RPN) in a large multi-institutional study
Introduction
For T1 renal lesions, open partial nephrectomy (OPN) offers equivalent oncological efficacy with the benefit of preserved renal function compared to radical nephrectomy (RN) [1] [2] [3] . Historically, T1b tumours (>4 cm) were treated with RN, but given the increased risk of chronic kidney disease (CKD) and resulting cardiac morbidity and mortality from RN, PN has been recommended as the treatment of choice for T1a and T1b lesions when technically feasible [4] [5] [6] . Improved overall survival is thought to be another advantage of PN; however, no benefit in survival was shown in a randomised controlled trial comparing PN to RN [7] .
Minimally invasive PN has the benefit of decreased morbidity and quicker recovery compared to the OPN. Obstacles to the wider use of laparoscopic PN, including a steep learning curve, were overcome with robotic assistance. Robotic partial nephrectomy (RPN) provides numerous benefits compared to pure laparoscopic PN and is now being performed with greater frequency at centres where robotic technology is available [8, 9] . Increased experience with RPN has facilitated excision of increasingly complex lesions, whilst maintaining excellent outcomes [10] . Many centres now have robust experience with RPN, including removal of complex renal lesions such as T1b, completely endophytic, and hilar renal lesions.
Tumour complexity can increase the technical challenge of PN, resulting in potentially higher rates of collecting system entry, longer warm ischaemia time (WIT) and resultant renal injury [11] . However, comparisons of RPN for T1a and T1b lesions are limited with the largest series to date including only 83 T1b patients [12] . To add greater precision in estimating outcomes shown in previous reports, we report on the clinical and pathological characteristics of patients with cT1a or cT1b renal masses undergoing RPN and compare perioperative and functional outcomes between these cohorts in the largest multi-institutional study to date.
Patients and Methods
After Institutional Review Board approval from the respective institutions, data were reviewed from 1868 consecutive patients undergoing RPN by six surgeons at six institutions between 2006 and 2016. Patients excluded were those with multiple ipsilateral tumours removed during RPN (n = 41), previous nephrectomy (n = 44), a tumour thrombus (n = 25), solitary kidney (n = 25), and patients with a tumour >cT1b or no tumour size data available (n = 63). There were 1 684 patients who met eligibility criteria including 1 307 (77.6%) patients with a cT1a renal mass and 377 (22.4%) with a cT1b renal mass. Designation of clinical stage was determined by radiographic measurement of maximum tumour dimension, and patients were stratified into two groups based on a tumour size of >4 or ≤4 cm.
Demographic and clinical characteristics of patients undergoing RPN were compared, including patient age, sex, body mass index (BMI), age-adjusted Charlson Comorbidity Index (CCI), specific comorbidities, baseline estimated GFR (eGFR, mL/min/1.73 m 2 ), baseline CKD stage ≥3, prior abdominal surgeries, tumour size (cm), R.E.N.A.L. (Radius; Exophytic/Endophytic; Nearness; Anterior/Posterior; Location) nephrometry score, tumour laterality, tumour location (pole, anterior/posterior, hilar), date of surgery, approach (retroperitoneal vs transperitoneal), and clamp technique (main arterial, selective arterial, off-clamp).
Perioperative and functional outcomes were compared including: operative time; WIT; estimated blood loss (EBL); collecting system entry; intraoperative complications; conversion to RN; conversion to OPN; length of stay; percentage change in eGFR at discharge and acute kidney injury (AKI); postoperative complications including overall, medical, surgical, and major (Clavien-Dindo Grade ≥III); positive surgical margins (PSM) amongst malignant cases; maximum time to follow-up; percentage change in eGFR; and progression of CKD stage at most-recent follow-up (median 12.2 months, interquartile range 6.0-25.7, range 2.9-106.2).
Perioperative and functional outcomes were compared in univariable analysis (Mann-Whitney U and chi-squared tests of independence) and multivariable regression analysis (linear, logistic, Cox proportion hazards) adjusting for surgeon performing the RPN and date of surgery.
Results

Demographic and Clinical Characteristics
In all, 1 307 and 377 patients underwent RPN for cT1a and cT1b lesions, respectively. Demographic data were similar between the cohorts. The median age (P = 0.427) and BMI (P = 0.407) were similar between the groups. The median age adjusted CCI was 3 for each group (P = 0.267). Significantly more patients had CKD stage ≥3 in the cT1b cohort (20.2% vs 14.5%, P = 0.008). The median date of surgery was later for T1b vs T1a masses (2013 vs 2012, P < 0.001).
As expected, tumour size was larger (5.0 vs 2.5 cm, P < 0.001) and the R.E.N.A.L. nephrometry score was greater (9 vs 7, P < 0.001) for the cT1b cohort. Excluding the radius component and looking strictly at the 'E.N.L.' components of the nephrometry score, cT1b tumours were still found to be more complex with a higher modified nephrometry score (7 vs 6, P < 0.001). The mass was more likely to be hilar in the cT1b group (24.6% vs 12.8%, P < 0.001). Clamp technique was also significantly different between the cohorts, with a lesser proportion of patients in the cT1b cohort having selective arterial clamping (6.6% vs 10.8%, P < 0.001) or surgery off-clamp (4.6% vs 8.9%, P < 0.001).
Outcomes Analysis
In univariable analysis, cT1b was associated with longer operative time (190.0 vs 159.0 min, P < 0.001), longer WIT (18.8 vs 15.0 min, P < 0.001), higher EBL (150.0 vs 100.0 mL, P < 0.001), more collecting system entry (76.9% vs 45.6%, P < 0.001), more intraoperative complications (5.6% vs 2.4%, P = 0.034), and more surgical postoperative complications (10.1% vs 5.7%, P = 0.002). There was a greater incidence of AKI at discharge for cT1b tumours (36.3% vs 20.3%, odds ratio [OR] 1.94, P < 0.001) ( Table 1) .
Results were similar in multivariable analysis (Table 2) , with additional findings including more overall postoperative complications (13.6% vs 10.5%, OR 1.55, P = 0.015) and longer length of stay (P < 0.001) associated with cT1b masses. There were no differences in the risk of progression of CKD stage at 12.2 months (27.9% vs 25.6%, P = 0.137), PSM, or major postoperative complications. There was also no significant percentage change in eGFR with latest follow-up on multivariable analysis (À12.4% vs À8.5%, P = 0.156).
There were no differences in PSM amongst malignant cases (3.0% vs 4.6%, P = 0.228) or major postoperative complications (3.7% vs 3.6%, P = 0.917). On multivariable analysis, there was a higher risk of Clavien-Dindo Grade II vs Clavien-Dindo Grade I or no complication in the cT1b group (OR 1.71, P = 0.013) ( Table 3) .
Discussion
Robotic partial nephrectomy is associated with excellent oncological and functional outcomes for T1a renal masses [13] . As experience with RPN has matured, as reports show the safety of RPN for complex lesions, and as guidelines have endorsed the use of PN for T1b lesions, indications for RPN have expanded beyond T1a lesions to include T1b masses [5, 14] . Pure laparoscopic PN and RPN for T1b tumours demonstrate similar oncological and functional outcomes, supporting minimally invasive nephron-sparing surgery when possible [15] . Whether secondary to increasing experience and skill with RPN and/or the growing body of literature supporting the use of RPN for T1b lesions, our present results confirm that RPN has more recently been utilised for T1b lesions at our centres, as indicated by a more contemporary median date of surgery than for T1a lesions (2013 vs 2012, P < 0.001).
Multiple publications have shown the safety and feasibility of RPN for T1b renal lesions, although studies are smaller and some findings are conflicting [12, [16] [17] [18] [19] [20] [21] . In all prior studies comparing outcomes of RPN for T1b/T1b+ vs T1a lesions, WIT was longer for T1b lesions and PSM were similar (Table 4) . In most studies, EBL was greater for T1b masses and there was no significant difference in the rate of complications.
Our present series included 377 patients with a cT1b mass, whilst the next largest published series by Petros et al. [12] included 83 patients with tumours of >4 cm. Similar to other studies, WIT and operative time were longer for T1b renal lesions. The median WIT for T1b masses was 18.8 min, well below a threshold of 25 min, and the median EBL and operative time were amongst the lowest compared with previous reports, probably reflecting the cumulative experience of the surgeons and surgical teams in our present study. With increasing experience, some of these cases can be performed off clamp; 17 (4.6%) of the T1b cases were performed off-clamp in the present study.
Although we report the shortest WIT for T1b tumours to date, WIT can be anticipated to be longer for more complex renal lesions even in the most experienced hands, and there is potentially a greater positive impact of selective renal vessel clamping on renal function. To better facilitate selective renal vessel clamping, near-infrared fluorescence imaging with use of indocyanine green dye has been used by other groups and was also used in many cases in the present study [22, 23] .
There was only one conversion to a RN in the T1b cohort. Our present study suggests that there may be more intraoperative complications for RPN for T1b lesions, although this finding did not reach statistical significance (5.6% vs 2.4%, P = 0.055). Similar to Ficarra et al. [17] , there were significantly more postoperative complications in the T1b group (13.6% vs 10.5%, P = 0.015). Stratification of complications showed that there were significantly more surgical postoperative complications (10.1% vs 5.7%, P < 0.001) and a higher risk of Clavien-Dindo Grade II complications but no greater risk of Clavien-Dindo Grade ≥III complications. A greater risk of urine leak could be anticipated, with nearly a 70% increased risk of collecting system entry noted in the T1b group. Although a greater proportion of complications were surgical in the T1b cohort, there was not a significantly greater incidence of overall postoperative complications. Additionally, the overall complication rate of 13.6% appears to be comparable to other RPN studies for T1b tumours (Table 4) . Although there was a higher risk of minor complications, no difference in major complications suggests that RPN for T1b tumours is safe. Whether the size of renal tumour or other factors associated with T1b lesions contributed more to surgical complications is unclear. Our present analysis did show that T1b lesions were more complex than T1a lesions irrespective of tumour size as the modified nephrometry score, which excluded the maximal diameter of the renal lesion, was significantly greater for T1b lesions.
The oncological outcome of PN for larger renal masses is of particular importance as there is an inherently greater risk of local tumour recurrence while preserving the affected kidney. Larger tumours may raise concern for increased risk of recurrence. Tumour size of >4 cm and PSM are associated with a significantly increased risk of ipsilateral tumour recurrence [24] . PSM with high-risk disease, pT2-pT3a or Fuhrman grade III-IV at PN is also associated with a greater risk of tumour recurrence [25] . Upstaging to pT3a disease is also more common with cT1b than cT1a disease; furthermore, PN is associated with shorter recurrence-free survival for pT3a disease [26] . Although only long-term follow-up will be a true measure of oncological success, and follow-up was limited to a median of 11.5 months for the T1b cohort, the rate of PSM was similar between the groups and is thus in agreement with previously published reports that all show no significant difference in the PSM rate. Furthermore, our present PSM rate (3.0%) is consistent with previous reports ranging from 0% to 6.8% (Table 4) . Prior studies have shown no difference in long-term oncological outcomes for OPN in T1b renal masses. Previous RPN studies for cT1b tumours show no difference in recurrence at 22 months [17, 18] , progression-free survival at 23 months [19] , or cancerspecific survival at 24.3 months [20] . We would anticipate similar long-term oncological outcomes for T1a and T1b masses after RPN.
Similar to prior studies, we show that functional outcomes are only mildly impacted by RPN for T1b masses. There was a greater risk of AKI at discharge for cT1b patients, which was probably due to the greater parenchymal loss and longer WIT. However, at a median follow-up of 12 months, there was only a À12.4% change in eGFR for cT1b renal masses, with only 27.9% of patients having progression of CKD and no differences compared to cT1a renal masses in multivariable analysis. This is consistent with previous reports showing similar renal function outcomes for cT1a and cT1b renal masses [12, 16, [18] [19] [20] , but conflicts with the study by Janda et al. [21] showing a greater mean change in postoperative eGFR for T1b patients.
The present study is the largest, multicentre study evaluating outcomes of RPN for T1a vs T1b tumours. However, limitations of the present study do exist. There are inherent biases given that this is a retrospective study. As evidenced by the disproportionate number of patients in the T1a group, selection bias is a factor in our present study. Although follow-up is~12 months, our intermediate follow-up is another limitation as longer-term follow-up would be particularly important for monitoring functional and oncological outcomes, including survival. 
Conclusions
In the largest multi-institutional study of RPN for T1b renal lesions to date, RPN for T1b lesions was safe, had a low risk of PSM, and was effective in preserving renal function. RPN should be considered for T1b lesions when anatomically and clinically feasible but should ideally be performed by surgeons and supporting teams with ample experience.
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